A study in the Annals of Internal Medicine found that the incidence of gout is significantly lower among patients with type 2 diabetes who took sodium-glucose cotransporter-2 inhibitors, compared with patients who took glucagon-like peptide-1 receptor agonists. Researchers reviewed data from 295,907 adults and suggested that "SGLT2 inhibitors might be an effective class of medication for the prevention of gout for patients with diabetes or metabolic disorders."
Study: SGLT2 inhibitors may reduce gout incidence in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.